IRINOTECAN HYDROCHLOIDE
Manufacturer: BluePoint Laboratories
Score: 148.0
Irinotecan hydrochloride is an antineoplastic agent used in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for the treatment of metastatic carcinoma of the colon or rectum. It is also used as a single agent for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. The drug works by inhibiting topoisomerase I, an enzyme involved in DNA replication. Common adverse reactions include diarrhea, nausea, vomiting, abdominal pain, and neutropenia. The recommended dosage is 125 mg/m2 to 350 mg/m2, depending on the regimen and patient population. Special considerations are needed for patients with reduced UGT1A1 activity, pregnant or nursing women, pediatric patients, and geriatric patients.
Diarrhea and myelosuppression can be life-threatening
Reduce dose by one level for patients with prior pelvic/abdominal radiotherapy, performance status of 2, or increased bilirubin levels
125 mg/m2 to 350 mg/m2
Not established